Medtech startups occupy a middle ground between software and therapeutics: they typically have shorter regulatory pathways than drugs, but longer development and reimbursement cycles than most software products. That hybrid profile means medtech founders need a valuation toolkit that blends traditional venture heuristics with milestone-based thinking borrowed from life sciences. Here's how investors typically approach the problem.
Why medtech valuation is different
A medical device or diagnostics company's value is driven heavily by regulatory milestones (510(k) clearance, PMA approval, CE marking), clinical evidence generation, and reimbursement codes, rather than purely by revenue growth. Unlike a typical software business, a medtech company can be pre-revenue for years while still accumulating substantial enterprise value through de-risking events. This is conceptually similar to the dynamics we cover in valuation models for biotechnology startups, though medtech's regulatory and reimbursement risks differ meaningfully from drug development risk. A device company also carries manufacturing, supply chain, and quality-system risk that a typical therapeutics asset does not, since investors need to underwrite the company's ability to actually produce and distribute the product at scale once it clears regulatory hurdles.
Risk-adjusted milestone valuation
One of the most common frameworks for medtech is a risk-adjusted milestone model, where the company's projected value at each future milestone (first-in-human study, regulatory clearance, first commercial sale, reimbursement approval) is discounted by the probability of reaching that milestone and by time value of money. This produces a present-value estimate that reflects both the size of the opportunity and the real odds of getting there, rather than assuming a straight-line path to commercialization. In practice, investors will assign a probability of technical and regulatory success (PTRS) to each stage gate, often informed by historical approval rates for comparable device categories, and then discount future cash flows back using a venture-appropriate discount rate that reflects both market risk and the binary nature of regulatory outcomes. Because these probabilities compound across multiple gates, even modest changes in assumed success rates at an early milestone can meaningfully swing the implied valuation, which is why founders should be prepared to defend the data behind their own risk assumptions rather than simply adopting industry averages.
Comparable transactions and precedent rounds
Because many medtech companies lack revenue for extended periods, investors frequently lean on comparable private financing rounds and M&A transactions within the same device category and regulatory stage. A diagnostics company nearing FDA clearance, for example, might be benchmarked against recent rounds raised by similarly staged diagnostics peers rather than against discounted cash flows. This comparables approach overlaps with how investors apply the venture capital method to back into a present valuation from an assumed future exit multiple. Precedent transaction data can be harder to source in medtech than in software, since many device deals are private and terms are rarely disclosed in full, so experienced investors and advisors often rely on a combination of public disclosures, industry databases, and informal benchmarking conversations with other investors active in the same therapeutic or device category.
The cost-to-replicate and sum-of-the-parts lens
For device companies with substantial IP and engineering investment but limited clinical data, some early investors will also sanity-check valuation against the cost to replicate the technology and team — essentially, what it would cost a well-funded competitor to build the same asset from scratch. This is rarely the primary method used to set a round's price, but it serves as a useful floor in negotiations. A related sum-of-the-parts lens can also be useful for multi-product medtech platforms, where different product lines may sit at very different regulatory and commercial stages; rather than valuing the company as a single blended asset, investors sometimes value each product line separately against its own milestone timeline and then sum the pieces, which can surface meaningfully different conclusions than a single company-wide multiple would.
Reimbursement risk deserves its own line item
Even after a device clears FDA or CE marking hurdles, commercial success depends heavily on securing favorable reimbursement codes and coverage decisions from payers such as the Centers for Medicare & Medicaid Services and private insurers. Many promising devices have stalled commercially not because the technology failed, but because reimbursement pathways were unclear or reimbursement rates were too low to support a viable sales model. Sophisticated investors increasingly treat reimbursement strategy as its own milestone in the valuation model, distinct from regulatory clearance, and will ask founders for a clear-eyed view of the relevant payer landscape, existing CPT or HCPCS codes, and any health economics data needed to support a new code application.
Structuring the round around milestones
Given the binary nature of regulatory and reimbursement outcomes, medtech rounds are often structured with tranches tied to specific milestones rather than a single lump-sum investment. Founders should understand how these structures interact with liquidation preferences and anti-dilution terms, since milestone-based financings can materially change effective ownership if targets are missed or delayed. A clean, well-modeled cap table that reflects tranche scenarios will make these conversations much easier with your board and new investors. It's also worth modeling downside scenarios explicitly: if a milestone slips by two or three quarters, which is common in regulatory-dependent businesses, founders should know in advance how that delay affects runway, the timing of the next tranche, and the company's negotiating position with existing and prospective investors.
Working with your CFO or finance lead
Because medtech valuation requires blending regulatory timelines, reimbursement modeling, and venture return math, it's an area where an experienced CFO or fractional finance lead can add significant value well before a raise begins, by building the milestone model investors will expect to see in diligence. A strong finance lead will also help translate clinical and regulatory milestones into the financial language investors use, so that a complex, multi-year development plan can be summarized clearly in a model that a generalist venture partner can underwrite with confidence.
Closing thoughts
Medtech valuation isn't a single formula — it's a blend of risk-adjusted milestone modeling, comparable transactions, and negotiation grounded in regulatory reality. If you're preparing to raise a Series A or Series B for a medical device or diagnostics company, book a free consult with Quantum Growth Advisors to pressure-test your valuation approach before you go to market.